Literature DB >> 25667434

The impact of biological therapy on regulatory T cells in rheumatoid arthritis.

Rachel Byng-Maddick1, Michael R Ehrenstein2.   

Abstract

Regulatory T cells (Treg) are functionally defective in patients with RA. Restoring their function may not only control inflammation but also restore tolerance in these patients. Biologic therapies have been tremendously successful in treating RA. Here we review numerous reports suggesting that these immunomodulatory therapies have an impact on Treg and that this may contribute to their beneficial effects. Better understanding of their mode of action may not only lead to improvements in therapies and sustained remission but also enable the development of biomarkers of response, which would be the first steps towards personalized medicine.
© The Author 2015. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  anti-TNF therapy; biologic therapy; regulatory T cells; rheumatoid arthritis

Mesh:

Substances:

Year:  2015        PMID: 25667434     DOI: 10.1093/rheumatology/keu487

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  28 in total

Review 1.  Immunology of idiopathic nephrotic syndrome.

Authors:  Manuela Colucci; Giorgia Corpetti; Francesco Emma; Marina Vivarelli
Journal:  Pediatr Nephrol       Date:  2017-04-27       Impact factor: 3.714

2.  Dysregulated ICOS+ proinflammatory and suppressive regulatory T cells in patients with rheumatoid arthritis.

Authors:  Hong-Xia Wang; Xia Kang; Shuai Chu; Haixia Li; Xin Li; Xiaofeng Yin; Yu-Rong Qiu; Weinan Lai
Journal:  Exp Ther Med       Date:  2018-08-24       Impact factor: 2.447

3.  Infliximab therapy balances regulatory T cells, tumour necrosis factor receptor 2 (TNFR2) expression and soluble TNFR2 in sarcoidosis.

Authors:  A Verwoerd; D Hijdra; A D M Vorselaars; H A Crommelin; C H M van Moorsel; J C Grutters; A M E Claessen
Journal:  Clin Exp Immunol       Date:  2016-07-12       Impact factor: 4.330

4.  Intranasal administration of abatacept enhances IL-35+ and IL-10+ producing Bregs in lung tissues of ovalbumin-sensitized asthmatic mice model.

Authors:  Maha Fahad Alenazy; Fatemeh Saheb Sharif-Askari; Mohammed S El-Wetidy; Narjes Saheb Sharif-Askari; Ibrahim Yaseen Hachim; Mohammad-Hani Temsah; Basema Saddik; Roua Al-Kufaidy; Maha A Omair; Yasser A Alshawakir; Amany Adulgadel Fathaddin; Suad Hannawi; Qutayba Hamid; Mohammed A Omair; Saleh Al-Muhsen; Rabih Halwani
Journal:  PLoS One       Date:  2022-09-06       Impact factor: 3.752

5.  Foxp3 and Toll-like receptor signaling balance Treg cell anabolic metabolism for suppression.

Authors:  Valerie A Gerriets; Rigel J Kishton; Marc O Johnson; Sivan Cohen; Peter J Siska; Amanda G Nichols; Marc O Warmoes; Aguirre A de Cubas; Nancie J MacIver; Jason W Locasale; Laurence A Turka; Andrew D Wells; Jeffrey C Rathmell
Journal:  Nat Immunol       Date:  2016-10-03       Impact factor: 25.606

6.  Stimulation of TNF receptor type 2 expands regulatory T cells and ameliorates established collagen-induced arthritis in mice.

Authors:  Vanessa Lamontain; Tobias Schmid; Dorothea Weber-Steffens; David Zeller; Zsuzsa Jenei-Lanzl; Harald Wajant; Rainer H Straub; Daniela N Männel
Journal:  Cell Mol Immunol       Date:  2018-01-29       Impact factor: 11.530

Review 7.  Insights into the biology and therapeutic implications of TNF and regulatory T cells.

Authors:  Benoit L Salomon
Journal:  Nat Rev Rheumatol       Date:  2021-07-05       Impact factor: 20.543

8.  Low-dose IL-2 therapy limits the reduction in absolute numbers of circulating regulatory T cells in rheumatoid arthritis.

Authors:  Sheng-Xiao Zhang; Jia Wang; Cai-Hong Wang; Rui-Huan Jia; Ming Yan; Fang-Yuan Hu; Guang-Ying Liu; Xue-Yu Liu; Jing Luo; Chong Gao; Xiao-Feng Li
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-04-28       Impact factor: 5.346

Review 9.  Immunopathogenesis of Rheumatoid Arthritis.

Authors:  Gary S Firestein; Iain B McInnes
Journal:  Immunity       Date:  2017-02-21       Impact factor: 31.745

Review 10.  Tregalizumab - A Monoclonal Antibody to Target Regulatory T Cells.

Authors:  Martin König; Faiza Rharbaoui; Silke Aigner; Benjamin Dälken; Jörg Schüttrumpf
Journal:  Front Immunol       Date:  2016-01-25       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.